ArticleBioinformation2025
Neuroendocrine tumors: A tertiary care hospital study on clinicopathology features and prognosis.
Article in Bioinformation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroendocrine tumors (NETs) are rare, heterogeneous malignancies with variable progression and diverse clinical manifestations. Therefore, it is of interest to analyze 12 histologically and immunohistochemically confirmed NET cases diagnosed between 2021 and 2025. Biopsies were obtained from primary or metastatic sites and tumor grading was determined using histomorphology and Ki-67 index. The median age at diagnosis was 60 years (range 17-87), with a male predominance (M:F = 1.4:1). The stomach was the most common primary site (33%). Seven patients (59%) had nonfunctional symptoms, while five (41%) presented with functional manifestations such as hypoglycemia, abdominal distension and diarrhea. Metastatic disease was noted in 33% of cases. Chemotherapy was administered in two grade III NETs. Overall survival was 100% in grades I and II, whereas grade III had a mean survival of 15 months. NETs require precise histopathologic and immunohistochemical differentiation, particularly in high-grade forms, to enable timely diagnosis and improved management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.